Howard Feldman, MD, FRCP(C), FAAN (Neurology)
Professor AdjunctAbout
Research
Overview
Medical Subject Headings (MeSH)
Dementia; Information Science; Named Groups
ORCID
0000-0002-9258-4538
Research at a Glance
Yale Co-Authors
Frequent collaborators of Howard Feldman's published research.
Publications Timeline
A big-picture view of Howard Feldman's research output by year.
James Brewer
Vladimir Coric, MD
29Publications
47Citations
Publications
2024
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
Matthews D, Kinney J, Ritter A, Andrews R, Strom E, Lukic A, Koenig L, Revta C, Fillit H, Zhong K, Tousi B, Leverenz J, Feldman H, Cummings J. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12490. PMID: 38988416, PMCID: PMC11233274, DOI: 10.1002/trc2.12490.Peer-Reviewed Original ResearchAltmetricConceptsFluorodeoxyglucose positron emission tomographyGlial fibrillary acidic proteinPositron emission tomographyMagnetic resonance imagingPlasma biomarkersVolumetric magnetic resonance imagingMild to moderate ADFDG positron emission tomographyPhase 2 clinical trialNeurofilament light chainGlial fibrillary acidic protein concentrationFibrillary acidic proteinInflammation-related proteinsTemporal cortexLeft inferior temporal cortexModerate ADCognitive endpointsFluorodeoxyglucosePET uptakeInflammation biomarkersBaseline MMSEMild-to-moderate Alzheimer's disease patientsImaging biomarkersBiomarker heterogeneityEmission tomographyA multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease
Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R, Momper J, Thomas R, Rissman R, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman H. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimer's Research & Therapy 2024, 16: 151. PMID: 38970127, PMCID: PMC11225352, DOI: 10.1186/s13195-024-01490-z.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsOrally administered small moleculeFractional synthesis rateAscending dose studyDose-dependent loweringIRB-approved protocolEarly ADMini-Mental State ExamDose-dependent effectAlzheimer's diseaseBlood patchDouble-blindWell-toleratedCatheter placementPreclinical modelsLumbar punctureDose studyIntravenous infusionMild cognitive impairmentEvaluate safetyPlacebo participantsCognitive measuresStable isotope labeling kineticsActive drugClinical trialsADAS-Cog12Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease
Morales J, Gabriel N, Natarajan L, LaCroix A, Shadyab A, Xu R, Silverman J, Feldman H, Hernandez I, Collaboration F. Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease. Alzheimer's & Dementia 2024 DOI: 10.1002/alz.13872.Peer-Reviewed Original ResearchAltmetricConceptsRisk of ADCross-sectional analysis of electronic health recordsAnalysis of electronic health recordsAD riskAssociated with risk of ADAssociated with AD riskAssociated with decreased prevalenceElectronic health recordsRetrospective cohort study designMedicare claims dataCohort study designCox proportional hazards regressionAssociated with riskCross-sectional analysisProportional hazards regressionPrevalence of ADMultiple sensitivity analysesAlzheimer's diseaseHealth recordsMedicare beneficiariesMedicare dataClaims dataStudy designHazards regressionPatient characteristicsProtocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)
Feldman H, Luchsinger J, Léger G, Taylor C, Jacobs D, Salmon D, Edland S, Messer K, Revta C, Flowers S, Jones K, Koulman A, Yarasheski K, Verghese P, Venkatesh V, Zetterberg H, Durant J, Lupo J, Gibson G, Group F. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam). PLOS ONE 2024, 19: e0302998. PMID: 38809849, PMCID: PMC11135745, DOI: 10.1371/journal.pone.0302998.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsPhase 2bPhase 2aRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialCo-primary efficacy endpointsTolerability eventsBest-tolerated dosePlacebo-controlled trialWell-tolerated dosesAlzheimer's diseaseLonger-term safetyEfficacy of drug deliveryWeeks of treatmentTargeted therapeutic approachesErythrocyte transketolase activityGroups of participantsDouble-blindPlacebo armEfficacy endpointSecondary endpointsOral treatmentPharmacokinetic measurementsClinical trialsTherapeutic approachesBlood markersPersonal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective
Patel K, Yang D, Feldman H, Hsiung G, Nygaard H, Best J, Dwosh E, Robillard J, DeMarco M. Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12463. PMID: 38596482, PMCID: PMC10999946, DOI: 10.1002/trc2.12463.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCare partnersSemi-structured phone interviewsCare partner perspectivesCare partners' experiencesPatients' decision-making processPre-test counsellingRoutine medical careBiomarker testingHealthy behaviorsCaregiving responsibilitiesPost-disclosureRoutine carePositive lifestyleLifestyle changesPhone interviewsMedical carePartners' experiencesCarePartner's perspectiveMedical interventionsAlzheimer's diseaseObservational studyClinic patientsStudy findingsPositive feelingsClinical value of Alzheimer's disease biomarker testing
Patel K, Yang D, Best J, Chambers C, Lee P, Henri‐Bhargava A, Funnell C, Foti D, Pettersen J, Feldman H, Nygaard H, Hsiung G, DeMarco M. Clinical value of Alzheimer's disease biomarker testing. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12464. PMID: 38596484, PMCID: PMC10999950, DOI: 10.1002/trc2.12464.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAD biomarker testsHealth care resource useLevel of cognitive impairmentCare resource useLongitudinal cohort studyRoutine medical careAlzheimer's Disease DiagnosticHealth system economicsBiomarker testingClinical management planMedical decision-makingDementia specialistsMemory clinicIncreased referralsBaseline clinical presentationQuestionnaires pre-Increase patientsAD biomarker profileMedical careMedical utilizationFamily members' counselingManagement questionnaireCohort studyDrug prescriptionsPersonal utilityDeveloping the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program
Moukarzel S, Zlatar Z, Hartman S, Lomas D, Feldman H, Banks S, Group H. Developing the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2024, 10: e12457. PMID: 38440783, PMCID: PMC10909928, DOI: 10.1002/trc2.12457.Peer-Reviewed Original ResearchAltmetricConceptsHealthy actionsChanging support needsDelay dementia onsetCommunity advisory boardCultural adaptation frameworkIncreased self-efficacyPersonal goal settingRisk factorsModifiable risk factorsBehavioral changesPositive behavior changePublic health challengeEffect behavior changeCommunity feedbackSocial cognitive theoryDementia onsetProgram usabilitySupport needsADRDGoal settingHealth challengesMultidisciplinary teamSelf-efficacyPilot testAdvisory boardPotentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison
Son S, Speechley M, Zou G, Kivipelto M, Mangialasche F, Feldman H, Chertkow H, Belleville S, Nygaard H, Hachinski V, Pieruccini-Faria F, Montero-Odasso M. Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison. The Journal Of Prevention Of Alzheimer's Disease 2024, 1-10. DOI: 10.14283/jpad.2024.105.Peer-Reviewed Original ResearchAltmetricConceptsModifiable risk factorsCanadian Longitudinal StudyPhysical inactivityHearing lossDementia casesRisk factorsModifiable dementia risk factorsSleep disturbanceAssociated with modifiable risk factorsAssociated with less educationMidlife hearing lossTargeting physical inactivityDementia risk factorsDesignCross-sectional analysisLife course modelLongitudinal studyRisk reduction strategiesDementia preventionMidlife obesityMidlife hypertensionCanadian adultsLess educationPopulation impactObjectiveTo estimateTraumatic brain injury
2023
Number of completed exercise sessions is associated with slower brain atrophy in MCI over 12 months in the EXERT trial
Digma L, Aslanyan V, Brewer J, Bevins E, Katula J, Chmelo E, Hodge H, LaCroix A, Shadyab A, Jacobs D, Salmon D, Feldman H, Pa J, Baker L. Number of completed exercise sessions is associated with slower brain atrophy in MCI over 12 months in the EXERT trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079285.Peer-Reviewed Original ResearchConceptsSupervised exercise sessionsBrain atrophyExercise sessionsAlzheimer's Disease Cooperative StudyLess brain atrophySupervised exercise interventionLower dementia riskLate-life exerciseAmount of exerciseInferior lateral ventricleExercise armExercise interventionDementia riskBaseline ageCDR-SBAerobic trainingLateral ventricleHigh adherenceIntervention adherenceNumber of sessionsVentricular expansionExercise typePlasma Aβ42/40Amnestic MCICognitive declineCSF tau markers are associated with fine memory discrimination in older adults with amnestic MCI in the EXERT trial
Fenton L, Aslanyan V, Jacobs D, Salmon D, Brewer J, Rissman R, Feldman H, Shadyab A, LaCroix A, Baker L, Pa J. CSF tau markers are associated with fine memory discrimination in older adults with amnestic MCI in the EXERT trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.080157.Peer-Reviewed Original ResearchConceptsAmnestic mild cognitive impairmentMemory discriminationOlder adultsMemory testLogical memoryHippocampal volumeAuditory Verbal Learning TestLogical memory testVerbal Learning TestBehavioral pattern separationVerbal memory testsMedial temporal lobeLarger hippocampal volumesMemory measuresList learningStory recallLearning TestObject taskMemory assessmentCognitive performanceMild cognitive impairmentPattern separationCognitive AssessmentStructural brain imagesTemporal lobe